Literature DB >> 18636315

The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation.

Luci Bavaresco1, Andressa Bernardi, Elizandra Braganhol, Angélica Regina Cappellari, Liliana Rockenbach, Patrícia Fernandes Farias, Márcia Rosângela Wink, Andrés Delgado-Cañedo, Ana Maria Oliveira Battastini.   

Abstract

Malignant gliomas are the most common and devastating primary tumors in the brain and, despite treatment, patients with these tumors have a poor prognosis. The participation of ecto-5'-NT/CD73 per se as a proliferative factor, being involved in the control of cell growth, differentiation, invasion, migration and metastasis processes has been previously proposed. In the present study, we evaluated the activity and functions of ecto-5'-NT/CD73 during the proliferation process of rat C6 and human U138MG glioma cell lines. Increasing confluences and culture times led to an increase in ecto-5'-NT/CD73 activity in both C6 and U138MG glioma cells. RT-PCR analysis and flow cytometry analysis showed a significant increase in ecto-5'-NT/CD73 mRNA and protein levels, respectively, comparing confluent with sub-confluent cultures in human U138MG glioma cells. Ecto-5'-nucleotidase/CD73 may regulate the extracellular adenosine 5'-monophosphate (AMP) and adenosine levels. Treatment with 1 microM APCP, a competitive ecto-5'-NT/CD73 inhibitor, caused a significant reduction of 30% in glioma cell proliferation. In addition, 100 microM adenosine increases cell proliferation by 36%, and the treatment with adenosine plus NBTI and dipyridamole, produced an additional and significant increase of on cell proliferation. The inhibitory effect on cell proliferation caused by APCP was reverted by co-treatment with NBTI and dipyridamole. AMP (1 mM and 3 mM) decreased U138MG glioma cell proliferation by 29% and 42%, respectively. Taken together, these results suggest the participation of ecto-5'-NT/CD73 in cell proliferation and that this process is dependent upon the enzyme's production of adenosine, a proliferative factor, and removal of AMP, a toxic molecule for gliomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636315     DOI: 10.1007/s11010-008-9877-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  40 in total

1.  In vitro effect of extracellular AMP on MCF-7 breast cancer cells: inhibition of glycolysis and cell proliferation.

Authors:  F Hugo; S Mazurek; U Zander; E Eigenbrodt
Journal:  J Cell Physiol       Date:  1992-12       Impact factor: 6.384

2.  Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells.

Authors:  Li Wang; Xuerui Zhou; Tingting Zhou; Dong Ma; Sifeng Chen; Xiuling Zhi; Lianhua Yin; Zhimin Shao; Zhouluo Ou; Ping Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-02       Impact factor: 4.553

3.  Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates.

Authors:  S Mazurek; A Michel; E Eigenbrodt
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

4.  A direct colorimetric assay for Ca2+ -stimulated ATPase activity.

Authors:  K M Chan; D Delfert; K D Junger
Journal:  Anal Biochem       Date:  1986-09       Impact factor: 3.365

Review 5.  Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.

Authors:  G Ohana; S Bar-Yehuda; F Barer; P Fishman
Journal:  J Cell Physiol       Date:  2001-01       Impact factor: 6.384

6.  Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance.

Authors:  P Ujházy; E S Berleth; J M Pietkiewicz; H Kitano; J R Skaar; M J Ehrke; E Mihich
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

Review 7.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

8.  Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line.

Authors:  Elizandra Braganhol; Alessandra S K Tamajusuku; Andressa Bernardi; Márcia R Wink; Ana M O Battastini
Journal:  Biochim Biophys Acta       Date:  2007-06-16

9.  RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion.

Authors:  Xiuling Zhi; Sifeng Chen; Ping Zhou; Zhimin Shao; Li Wang; Zhouluo Ou; Lianhua Yin
Journal:  Clin Exp Metastasis       Date:  2007-06-21       Impact factor: 5.150

10.  CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73.

Authors:  L Airas; J Hellman; M Salmi; P Bono; T Puurunen; D J Smith; S Jalkanen
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  47 in total

1.  CD73 promotes tumor growth and metastasis.

Authors:  Bin Zhang
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Authors:  J H Azambuja; R S Schuh; L R Michels; I C Iser; L R Beckenkamp; G G Roliano; G S Lenz; J N Scholl; J Sévigny; M R Wink; M A Stefani; A M O Battastini; F Figueiró; H F Teixeira; E Braganhol
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

3.  Taurine postponed the replicative senescence of rat bone marrow-derived multipotent stromal cells in vitro.

Authors:  Huijiao Ji; Guiyun Zhao; Jingfeng Luo; Xiaoli Zhao; Ming Zhang
Journal:  Mol Cell Biochem       Date:  2012-04-25       Impact factor: 3.396

4.  CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling.

Authors:  Angela Yan; Michelle L Joachims; Linda F Thompson; Andrew D Miller; Peter D Canoll; Margaret S Bynoe
Journal:  J Neurosci       Date:  2019-03-29       Impact factor: 6.167

5.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

6.  Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.

Authors:  Fabrícia Dietrich; Fabrício Figueiró; Eduardo Cremonese Filippi-Chiela; Angélica Regina Cappellari; Liliana Rockenbach; Alain Tremblay; Patrícia Boni de Paula; Rafael Roesler; Aroldo Braga Filho; Jean Sévigny; Fernanda Bueno Morrone; Ana Maria Oliveira Battastini
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

7.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

8.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.

Authors:  Liliana Rockenbach; Elizandra Braganhol; Fabrícia Dietrich; Fabrício Figueiró; Manoella Pugliese; Maria Isabel Albano Edelweiss; Fernanda Bueno Morrone; Jean Sévigny; Ana Maria Oliveira Battastini
Journal:  Purinergic Signal       Date:  2014-01-26       Impact factor: 3.765

10.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors:  Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.